We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Clinical Chemistry Analyzers Detect Drugs of Abuse

By LabMedica International staff writers
Posted on 09 Jul 2009
Clinical chemistry analyzers use new reagents to detect 10 drugs of abuse (DoA) in human urine.

DoA tested for include cannabinoids (THC), cocaine metabolite, EDDP, ecstasy (MDMA), methadone, opiates, amphetamines, barbiturates, benzodiazepines, and ethanol.

Randox (Crumlin, UK) have launched DoA reagents for use on its RX series of clinical chemistry analyzers, RX Daytona and RX Imola. The analyzers and reagents provide systems that offer time, labor, and cost savings.

The RX Daytona is a compact, fully automated, random access analyzer with a throughput of 180 photometric tests and 270 independent security evaluators (ISE) tests per hour. The RX Imola is a fully automated random access benchtop analyzer capable of performing 400 photometric tests per hour and 240 ISE tests per hour. The analyzers are suitable for all types and sizes of laboratories.

Randox DoA assays are precise, stable, and accurate. The new assays are suited for use in police/crime laboratories, hospital laboratories, prison laboratories, as well as private screening laboratories. A comprehensive range of quality control sera is available.

Randox is an international diagnostics company that develops, manufactures, and markets clinical diagnostic products worldwide. Core products include clinical chemistry analyzers and reagents; biochip array technology; quality controls; and recombinant proteins and antibodies.

Related Links:

Randox


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS

Latest Clinical Chem. News

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
09 Jul 2009  |   Clinical Chem.

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
09 Jul 2009  |   Clinical Chem.

Low-Cost Portable Screening Test to Transform Kidney Disease Detection
09 Jul 2009  |   Clinical Chem.